1 source
FDA Approves Triple-Dose Wegovy Showing 21% Average Weight Loss
The US Food and Drug Administration approved 'Wegovy HD,' a higher-dose formulation of the weight-loss drug semaglutide tripling the previous maximum dose. Clinical trial participants lost an average of 21% of their body weight after 72 weeks, marking a significant advance in obesity pharmacotherapy.
Key Facts
- 1The FDA approved 'Wegovy HD', a formulation with triple the previous maximum dose of the weight-loss drug
- 2Participants in trials lost an average of 21% of their body weight after 72 weeks
Coverage
Reported by The Independent, with global significance for the rapidly expanding obesity treatment market and healthcare systems worldwide.